Principal Financial Group
RPRX icon

Principal Financial Group’s Royalty Pharma RPRX Stock Holding History

Principal Financial Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$27.1M Buy
464,355
+278,442
+150% +$16.4M 0.01% 776
2026
Q2 		$10.4M Buy
185,913
+175,588
+1,701% +$9.14M 0.01% 1390
2026
Q1 		$495K Sell
10,325
-349
-3% -$15.3K ﹤0.01% 2023
2025
Q4 		$412K Sell
10,674
-3,514
-25% -$134K ﹤0.01% 2066
2025
Q3 		$501K Sell
14,188
-2,116
-13% -$76.6K ﹤0.01% 2047
2025
Q2 		$587K Sell
16,304
-2,666
-14% -$88.3K ﹤0.01% 1969
2025
Q1 		$591K Sell
18,970
-1,146
-6% -$36.3K ﹤0.01% 1915
2024
Q4 		$513K Sell
20,116
-5,293
-21% -$140K ﹤0.01% 1961
2024
Q3 		$719K Sell
25,409
-3,704
-13% -$103K ﹤0.01% 1891
2024
Q2 		$768K Sell
29,113
-2,372
-8% -$65.8K ﹤0.01% 1888
2024
Q1 		$956K Buy
31,485
+8,086
+35% +$238K ﹤0.01% 1872
2023
Q4 		$657K Sell
23,399
-5,780
-20% -$159K ﹤0.01% 1896
2023
Q3 		$792K Buy
29,179
+1,514
+5% +$45K ﹤0.01% 1871
2023
Q2 		$850K Sell
27,665
-9,485
-26% -$321K ﹤0.01% 1864
2023
Q1 		$1.34M Buy
37,150
+1,528
+4% +$56.7K ﹤0.01% 1816
2022
Q4 		$1.41M Sell
35,622
-5,027
-12% -$210K ﹤0.01% 1815
2022
Q3 		$1.63M Sell
40,649
-5,783
-12% -$247K ﹤0.01% 1755
2022
Q2 		$1.95M Buy
46,432
+6,175
+15% +$253K ﹤0.01% 1812
2022
Q1 		$1.57M Buy
40,257
+2,168
+6% +$85.1K ﹤0.01% 1901
2021
Q4 		$1.52M Buy
38,089
+7,873
+26% +$306K ﹤0.01% 1906
2021
Q3 		$1.09M Sell
30,216
-1,507
-5% -$58.6K ﹤0.01% 1986
2021
Q2 		$1.3M Buy
31,723
+3,876
+14% +$165K ﹤0.01% 1991
2021
Q1 		$1.22M Buy
27,847
+14,256
+105% +$676K ﹤0.01% 1952
2020
Q4 		$680K Sell
13,591
-3,784
-22% -$161K ﹤0.01% 2035
2020
Q3 		$731K Buy
17,375
+6,375
+58% +$274K ﹤0.01% 1931
2020
Q2 		$534K Buy
+11,000
New +$544K ﹤0.01% 1955

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Principal Financial Group's RPRX Position: Q3 2026 in Review

Principal Financial Group increased its Royalty Pharma (RPRX) stake by 150% in Q3 2026, buying an estimated $16.4M and bringing the position to 464,355 shares worth $27.1M. The position accounts for 0.01% of the portfolio, ranked #776.

Principal Financial Group first reported a position in RPRX in Q2 2020 and has held it in 26 quarters since. 573 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • Principal Financial Group held 464,355 shares of Royalty Pharma worth $27.1M as of Q3 2026.
  • Principal Financial Group bought 278,442 Royalty Pharma shares in Q3 2026, an estimated $16.4M.
  • Royalty Pharma made up 0.01% of Principal Financial Group's portfolio in Q3 2026, its #776 holding.
  • Principal Financial Group first reported a position in Royalty Pharma in Q2 2020 and has held it in 26 quarters since.
  • 573 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Principal Financial Group's 13F filing for Q3 2026, filed 2 Nov 2026.